How Common Is Tuberculosis? Global and U.S. Stats

Tuberculosis remains one of the most common infectious disease killers on the planet, with an estimated 10.8 million new cases and 1.25 million deaths worldwide in 2023. That puts it ahead of HIV/AIDS in terms of lives lost to a single pathogen. In the United States, TB is far rarer but has been climbing since the pandemic, reaching its highest case count in a decade. Behind these headline numbers sits a much larger hidden burden: roughly a quarter of all people on Earth carry the bacterium without showing symptoms.

The Global Picture Right Now

The World Health Organization’s most recent estimates put global TB incidence at 10.8 million people in 2023, a rate of about 134 cases per 100,000 population and a slight increase from the year before.¹ Men account for a disproportionate share, roughly 5.8 million cases compared with 3.7 million in women and 1.2 million in children.² Deaths did fall by about 5% between 2022 and 2023, dipping to 1.25 million, which includes roughly 150,000 deaths among people also living with HIV.¹ That small decline in deaths is encouraging, but global incidence has been essentially flat or nudging upward, which means the world is far off track from the WHO’s 2025 End TB Strategy milestones.³

Latent Infection, the Massive Hidden Reservoir

Active TB is only the visible tip. Far more people carry the bacterium in a dormant state, where their immune system has walled off the infection but not cleared it. A systematic review drawing on both blood-based and skin-test surveys estimated that about a quarter of the world’s population has latent TB infection.⁴ A separate modeling study placed the absolute number at around 1.7 billion people as of 2014.⁵ The good news is that the proportion has been slowly falling, dropping from roughly 31% in 1990 to about 24% by 2019.⁶

Most people with latent TB never develop active disease. The lifetime risk of progression is commonly cited at 5–10%, though it climbs steeply for anyone whose immune system is compromised, whether from HIV, malnutrition, diabetes, or immunosuppressive medications. That enormous reservoir is why TB has been so stubbornly difficult to eradicate: even if you stop all new transmission today, billions of people already harbor the bacterium.

Where TB Hits Hardest

TB is overwhelmingly concentrated in lower-income regions. Most high-burden countries are in sub-Saharan Africa and Southeast Asia. India has the highest absolute number of cases, followed by China, Pakistan, and Indonesia.⁷ But when you look at rates per capita rather than total numbers, several African nations stand out: the Central African Republic, Lesotho, Namibia, and South Africa all had incidence rates above 300 per 100,000 in 2019, compared with fewer than 100 per 100,000 in Brazil, China, and Russia.⁷

To give you a sense of scale, a country with an incidence rate of 300 per 100,000 has more than 100 times the rate seen in the United States. The stark geography of TB is shaped by overlapping forces: poverty, HIV prevalence, overcrowded housing, and weaker health infrastructure all concentrate in the same regions.

Tuberculosis in the United States

TB in the U.S. is uncommon by global standards but has been rising. In 2023, the 50 states and Washington, D.C. reported 9,615 cases, a 16% jump from the 8,320 cases counted in 2022 and the highest number since 2013. The national rate climbed to 2.9 per 100,000, up from 2.5 the year before.⁸ That rate is still extraordinarily low compared with the global average of 134 per 100,000, but the upward trend has caught the attention of public health officials, especially since it exceeds even the 2019 pre-pandemic count.

Much of U.S. TB occurs among people born outside the country. Historically, rates among foreign-born adolescents have been nearly 20 times as high as among U.S.-born adolescents, and the disparity widens with age.⁹ This does not mean immigrants are spreading disease in any meaningful way; rather, many arrived with latent infections acquired in their home countries and later reactivated. Understanding this pattern matters because targeting latent TB testing and treatment in high-risk groups is the single most effective lever the U.S. has for pushing case counts back down.

How COVID-19 Disrupted TB Control

The pandemic dealt TB programs a serious blow. In 2020, global TB case notifications dropped by roughly 18% compared with 2019, not because fewer people were getting sick but because clinics were closed, resources were diverted, and patients stayed away from health facilities.¹⁰ The result was a wave of undiagnosed and untreated TB. By 2021, an estimated 10.6 million people fell ill with TB worldwide, a 4.5% increase from 2020, reversing years of slow decline. TB deaths, which had been trending downward since 2005, bounced back to 2017 levels.¹⁰

Modeling work projected the consequences for individual countries. Under even a mild disruption scenario, India alone could see an additional 182,000 TB cases and 83,600 excess TB deaths between 2020 and 2025. Under a severe disruption, TB incidence in modeled countries could rise by 3–9% and deaths by 4–16% over that period.¹¹ The pandemic essentially erased about five years of hard-won progress in global TB control.

Drug-Resistant TB

Standard TB treatment works well when the bacterium is susceptible to the front-line drugs, but resistance is a growing problem. A meta-analysis of 148 studies estimated the global pooled prevalence of multidrug-resistant TB (MDR-TB) at about 12% of TB cases overall.¹² That figure includes both new and previously treated patients, and rates vary enormously by setting; some countries in Eastern Europe and Central Asia have much higher proportions. Extensively drug-resistant TB, which resists additional second-line medications, was estimated at about 2.5% of TB cases in the same pooled analysis.¹²

In the United States, MDR-TB makes up only about 1–1.5% of all TB cases, but treating even a single case is expensive and grueling: patients require longer regimens of more toxic drugs, and the costs to the healthcare system are substantial.¹³ Among children and adolescents globally, MDR-TB incidence has been rising, with the steepest increases in the poorest regions and in Southern sub-Saharan Africa, Eastern Europe, and South Asia.¹⁴

The HIV-TB Collision

HIV and TB have been called the “dual epidemic” for good reason. HIV cripples the immune cells that hold latent TB in check, so co-infection dramatically raises the risk of progressing to active disease. A large meta-analysis pooling data from more than 13 million patients found that the overall prevalence of HIV-TB co-infection was about 14%, with the highest rates in Africa (22%) and North America (21%), followed by South America (16%), Europe (10%), and Asia (7%).¹⁵ The same analysis identified male sex, lower educational attainment, and drug-resistant TB as factors associated with higher co-infection rates.¹⁵ In practical terms, regions with high HIV prevalence and high TB prevalence suffer a compounding crisis where each disease fuels the other.

TB in Children

Children are among the most neglected populations in the TB epidemic. TB ranks among the top ten causes of death in children worldwide, yet most national health programs give pediatric TB low priority.¹⁶ Diagnosis is a major stumbling block: young children often cannot produce a sputum sample, and the tests validated for adults perform less reliably in pediatric populations. Trials of newer drugs and pediatric drug formulations have lagged behind adult medicine.¹⁶ The result is that the true scale of childhood TB is almost certainly underestimated, making an already large problem harder to measure and harder to solve.¹⁷

Crowding, Poverty, and the Social Roots of TB

TB is an airborne disease, and its spread is deeply tied to living conditions. A Brazilian study using multilevel analysis found that household crowding was independently and significantly associated with TB incidence, even after accounting for income and income inequality. Crowding essentially explained away the association between economic indicators and TB rates, suggesting it acts as the key pathway through which poverty drives transmission.¹⁸ This helps explain why TB persists so stubbornly in slums, prisons, and refugee camps, even when drug treatment is theoretically available. You cannot out-medicate a disease that keeps reinfecting people in shared air.

Subclinical Transmission and the Diagnosis Gap

A growing body of research is challenging the old assumption that only people coughing up bacteria can spread TB. Some individuals have what is called subclinical tuberculosis: they carry enough bacteria to test positive on a sputum smear but have no noticeable symptoms like chronic cough, weight loss, or fever. A study comparing household contacts found that children living with someone who had smear-positive subclinical TB had a similarly increased risk of becoming infected as children living with someone who had full-blown symptomatic TB.¹⁹ If confirmed at scale, this means that waiting for someone to feel sick before testing them misses a meaningful fraction of ongoing transmission. Reaching the WHO’s 2035 elimination targets will probably require active case-finding strategies that go beyond symptom-based screening.

Modern diagnostic tools are helping close the gap. The Xpert MTB/RIF assay, a rapid molecular test, has been deployed widely in high-burden countries. It can detect TB bacteria and rifampicin resistance in under two hours, a dramatic improvement over traditional methods that could take weeks. In modeled scenarios, switching from conventional microscopy to the Xpert test increased TB case detection from around 62–76% to 86–94%.²⁰ Faster diagnosis means patients start treatment sooner, which both saves lives and reduces the window during which they can infect others.²¹

BCG Vaccine: Why It Hasn’t Solved the Problem

The BCG vaccine, developed over a century ago, is one of the most widely administered vaccines in history. Most countries still give it to newborns, and it does a good job protecting young children against the most dangerous forms of TB, including meningitis and disseminated disease.²² Its protection against pulmonary TB in adults, however, is highly variable and generally weak. Some studies have found substantial benefit; others have found almost none. Part of the explanation may involve the biology of reinfection: BCG works better against disease from a first-time infection than against disease triggered by repeated exposures to new strains, which is exactly what happens in high-burden settings where the bacterium circulates constantly.²²

As some countries see declining TB rates, they have shifted from universal BCG vaccination to targeting only high-risk groups. That switch creates its own problems: it can be difficult to identify and reach everyone who qualifies, and coverage may drop.²³ Given BCG’s limited effectiveness in adults, there is broad agreement in the research community that a new vaccine is urgently needed. Several candidates are in clinical trials, but none has yet reached the point of replacing BCG.

Zoonotic Tuberculosis

Not all TB comes from human-to-human transmission. A related bacterium, Mycobacterium bovis, causes TB in cattle and can spill over into people, mainly through unpasteurized dairy products or close contact with infected livestock. Globally, zoonotic TB accounts for an estimated 1.4% of the total TB burden.²⁴ Outside Africa, the proportion was even lower in studies that measured it. In African countries, where raw dairy consumption and close livestock contact are more common, the median proportion was about 2.8%, which translates to a crude estimate of around 7 zoonotic TB cases per 100,000 people per year.²⁵

Zoonotic TB is frequently misidentified as ordinary human TB because standard laboratory tests do not distinguish between the species. That matters because M. bovis is inherently resistant to pyrazinamide, one of the four front-line TB drugs, so standard treatment regimens may be less effective if the zoonotic strain is not identified. In wealthy countries with mandatory pasteurization and cattle testing, zoonotic TB is rare. In pastoral communities across Africa and parts of Asia, it remains an underrecognized contributor to the overall burden.

1
PubMed Central. Review of the Global Burden of Tuberculosis in 2023: Insights from the WHO Global Tuberculosis Report 2024
2
PubMed. The Global Epidemiology of Tuberculosis: Burden, Trends, and Determinants
3
The Lancet Microbe. How Common Is Tuberculosis? Global and U.S. Stats
4
PubMed. The global prevalence of latent tuberculosis: a systematic review and meta-analysis
5
PLoS Medicine. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
6
PubMed. Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990-2019
7
PubMed Central. Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level
8
PubMed Central. Tuberculosis — United States, 2023
9
PubMed Central. Epidemiology of Tuberculosis Among US- and Foreign-Born Children and Adolescents in the United States, 1994–2007
10
PubMed Central. The impact of the COVID-19 pandemic on the global tuberculosis epidemic
11
The Lancet Global Health. Potential health service disruptions, economic and social impacts of COVID-19 and its mitigation
12
PubMed Central. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis
13
PubMed Central. Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007
14
Pediatric Research. Global burden of multidrug-resistant tuberculosis in children and adolescents
15
PubMed. Global prevalence of HIV and Mycobacterium tuberculosis co-infection: A systematic review and meta-analysis of 371 included articles
16
Clinical Infectious Diseases. Pediatric Tuberculosis: Global Overview and Challenges
17
PubMed Central. Epidemiology and disease burden of tuberculosis in children: a global perspective
18
PLoS ONE. Household crowding as a potential mediator of socioeconomic determinants of tuberculosis incidence in Brazil
19
PubMed Central. Disease Transmission by Patients With Subclinical Tuberculosis
20
PLoS Medicine. Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis
21
PubMed Central. Early detection of tuberculosis: a systematic review
22
Jornal de Pediatría. BCG vaccine: efficacy and indications for vaccination and revaccination
23
BMJ Open. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas
24
PubMed Central. Human zoonotic tuberculosis and livestock exposure in low‐ and middle‐income countries: A systematic review identifying challenges in laboratory diagnosis
25
PubMed Central. Zoonotic Mycobacterium bovis-induced tuberculosis in humans